Drug Trial Radar · NCT07211165
Clinical Study on the Mass Balance of Clifutinib
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Sep 29, 2025
Primary completion
Nov 5, 2025
Study completion Nov 12, 2025
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of \[14C\]Clifutinib, the distribution of total radioactivity in whole blood and plasma, and to determine the main excretion and metabolic pathways.
Conditions
- Healthy Adult Male
Interventions
[14C]ClifutinibDrug
The subjects are required to take the test drug on an empty stomach for at least 10 hours and without drinking water for 1 hour. After taking the drug, they should fast for 4 hours and refrain from drinking water for 1 hour.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-∞Time frame: From Day 1 of dosing to the Day 85 after dosing
- TmaxTime frame: From Day 1 of dosing to the Day 85 after dosing
- CmaxTime frame: From Day 1 of dosing to the Day 85 after dosing
- Percentage of metabolites in plasma relative to total exposure AUC (% AUC)Time frame: From Day 1 of dosing to the Day 85 after dosing
- The total radioactivityTime frame: From Day 1 of dosing to the Day 85 after dosing
- Identification of major metabolites in plasma, urine, and fecal samplesTime frame: From Day 1 of dosing to the Day 85 after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated hospital of Jiangnan University
Wuxi, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.